Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 27:33:100763.
doi: 10.1016/j.eclinm.2021.100763. eCollection 2021 Mar.

Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial

Dugald Seely  1   2   3 , Mark Legacy  1   2 , Rebecca C Auer  2 , Anna Fazekas  2 , Edita Delic  2 , Caitlin Anstee  2 , Leonard Angka  2 , Michael A Kennedy  2 , Lee-Hwa Tai  2 , Tinghua Zhang  2 , Donna E Maziak  2   4 , Farid M Shamji  2   4 , R Sudhir Sundaresan  2   4 , Sebastien Gilbert  2   4 , P James Villeneuve  2   4 , Ahmad S Ashrafi  5 , Richard Inculet  6 , Kazuhiro Yasufuku  7 , Thomas K Waddell  7 , Christian Finley  8 , Yaron Shargall  8 , Madelaine Plourde  9 , Dean A Fergusson  2   7 , Tim Ramsay  2 , Andrew J E Seely  2   4
Affiliations

Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial

Dugald Seely et al. EClinicalMedicine. .

Abstract

Background: Despite curative intent resection in patients with non-small cell lung cancer (NSCLC), recurrence leading to mortality remains too common. Melatonin has shown promise for the treatment of patients with lung cancer; however, its effect following cancer resection has not been studied. We evaluated if melatonin taken after complete resection reduces lung cancer recurrence and mortality, or impacts quality of life (QOL), symptomatology or immune function.

Methods: Participants received melatonin (20 mg) or placebo nightly for one year following surgical resection of primary NSCLC. The primary outcome was two-year disease-free survival (DFS). Secondary outcomes included five-year DFS, adverse events, QOL, fatigue, sleep, depression, anxiety, pain, and biomarkers assessing for immune function/inflammation. This study is registered at https://clinicaltrials.gov NCT00668707.

Findings: 709 patients across eight centres were randomized to melatonin (n = 356) versus placebo (n = 353). At two years, melatonin showed a relative risk of 1·01 (95% CI 0·83-1·22), p = 0·94 for DFS. At five years, melatonin showed a hazard ratio of 0·97 (95% CI 0·86-1·09), p = 0·84 for DFS. When stratified by cancer stage (I/II and III/IV), a hazard reduction of 25% (HR 0·75, 95% CI 0·61-0·92, p = 0·005) in five-year DFS was seen for participants in the treatment arm with advanced cancer (stage III/IV). No meaningful differences were seen in any other outcomes.

Interpretation: Adjuvant melatonin following resection of NSCLC does not affect DFS for patients with resected early stage NSCLC, yet may increase DFS in patients with late stage disease. Further study is needed to confirm this positive result. No beneficial effects were seen in QOL, symptoms, or immune function.

Funding: This study was funded by the Lotte and John Hecht Memorial Foundation and the Gateway for Cancer Research Foundation.

PubMed Disclaimer

Conflict of interest statement

Dr. Villeneuve reports ‘other’ from Minogue Medical, outside the submitted work. All other authors have no conflicts of interest to disclose.

Figures

Fig 1
Fig. 1
Consort Flow Diagram (Main Study). Includes all enrolled participants. ITT: intention to treat.
Fig 2
Fig. 2
Flow Diagram (Sub Study). Includes only those participants who were additionally enrolled in the sub-study.
Fig 3
Fig. 3
Five-Year Disease-Free Survival. Survival refers to the ratio of participants who have not experienced a recurrence or mortality at any given time. Stage I & II: Melatonin (n = 320); Placebo (n = 309). Stage III & IV: Melatonin (n = 34); Placebo (n = 41). Early Stage: Stage I & II; Late Stage: Stage III & IV. .
Fig 4
Fig. 4
NK Cell cytotoxicity. Left: Raw cytotoxicity values at baseline and six months. Right: Fold changes between baseline and six months. Cytotoxicity was quantified as either the amount of Cr51 released into the supernatant by dying Cr51-labelled K562 cells or the amount of CP450-labelled K562 cells that stain positive for propidium iodide. Error bars represent mean and 95% confidence interval. NS = not statistically significant; * = statistically significant.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Blanchon F., Grivaux M., Asselain B., Lebas F.-.X., Orlando J.-.P., Piquet J. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol. 2006 Oct;7(10):829–836. - PubMed
    1. Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J., Chirieac L.R. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017 Apr;15(4):504–535. - PubMed
    1. Osmani L., Askin F., Gabrielson E., Li Q.K. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin. Cancer Biol. 2018;52:103–109. - PMC - PubMed
    1. Miller V.A. Optimizing therapy in previously treated non-small cell lung cancer. Semin Oncol. 2006 Feb;33:S25–S31. 1 Suppl 1. - PubMed

Associated data

LinkOut - more resources